Introduction

For many years, the possibility of a causal relationship between lithiasis and carcinoma of the biliary tract has been under debate. In the gallbladder and extrahepatic bile tract, chronic inflammation has been accepted as a factor participating in the multistep process leading to cancer [10, 31]. It has also been associated with the presence of gastric and intestinal metaplasia and with pre-cancerous lesions [1–3, 5–7, 13, 15, 17]. By contrast, in intrahepatic bile duct carcinoma, the role of stones and inflammation is still controversial because hepatolithiasis is rare in Western countries, and more than 80% of cholangiocarcinomas have no history of predisposing factors [21].

Summary

Expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) helps to establish the origin of biliary and metastatic carcinomas. We investigated the expression of CK7 and CK20 in inflammatory, metaplastic and neoplastic conditions of the bile ducts, and evaluated possible relationships between the CK expression pattern and extrahepatic bile duct/gallbladder carcinomas (EBDCs) or intrahepatic bile duct carcinomas (IBDCs).

We used immunohistochemistry for the investigation of 48 formalin-fixed, paraffin-embedded specimens grouped as: A) lithiasic or inflamed surgically resected extrahepatic bile ducts/gallbladders: all were CK7+/CK20+; B) percutaneous liver biopsies from patients with chronic hepatitis C primary biliary cirrhosis and primary sclerosing cholangitis: all were CK7+/CK20+; C) EBDCs: all were CK7+/CK20, except for two cases which were CK7-/CK20; D) IBDCs: all were CK7+/CK20, except for one case showing CK20 positivity. Metaplastic changes were seen only among specimens in groups A and C: in these cases, CK20 was either focally or diffusely expressed.

Our study suggests that the expression of cytokeratins under specific stimuli can be different from normal tissues, and that sometimes CK20 expression can be related to and precede the occurrence of metaplastic alterations.

Key words: Cytokeratin 7 (CK7) – Cytokeratin 20 (CK20) – Bile duct tumors – Intestinal metaplasia

Introduction

For many years, the possibility of a causal relationship between lithiasis and carcinoma of the biliary tract has been under debate. In the gallbladder and extrahepatic bile tract, chronic inflammation has been accepted as a factor participating in the multistep process leading to cancer [10, 31]. It has also been associated with the presence of gastric and intestinal metaplasia and with pre-cancerous lesions [1–3, 5–7, 13, 15, 17]. By contrast, in intrahepatic bile duct carcinoma, the role of stones and inflammation is still controversial because hepatolithiasis is rare in Western countries, and more than 80% of cholangiocarcinomas have no history of predisposing factors [21].

The expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) in the biliary system has been assessed in a few studies, and the results are confusing [8, 26, 27]. Moll found that neoplasms usually repeat the same CK7 and CK20 expression pattern of the epithelia from which they originate [19]. Recently, Faa reported that CK20 is a “bile duct type” cytokeratin, and that its expression differs in experimental models of bile duct and oval cell proliferation, suggesting the existence of different mech-
organisms regulating proliferation and differentiation of biliary epithelial cells [9]. Molecular studies of cholangiocarcinogenesis in rat livers have shown that alterations induced by furan treatment (intestinal metaplasia and "type intestinal" of cholangiocarcinoma) are different from hyperplastic bile ductular alterations induced by common bile duct ligation [24]. Hence, different pathogenetic conditions appear to be responsible for the occurrence of bile duct carcinomas, and the correlation between inflammatory (lithiasis) or proliferative stimuli (ductular proliferation) and metaplastic alterations is still unclear.

In an attempt to clarify the relationship between metaplastic phenomena and the chain of events leading to bile duct cancer, we used immunohistochemical methods for the investigation of the expression pattern of CK7 and CK20 in the gallbladder and in the intra- and extrahepatic bile ducts, aiming to correlate the expression pattern of cytokeratins with conditions which usually precede the occurrence of bile duct neoplasia. Since an ultrastructural, histochemical and immunohistochemical similarity between the gallbladder and the extrahepatic bile ducts, both in normal and in neoplastic conditions is commonly accepted by various investigators [26, 27], we pooled together gallbladder and extrahepatic bile duct malignancy as “Extrahepatic Bile Duct Carcinoma” (EBDC), which is morphologically different from “Intrahepatic Bile Duct Carcinoma” (IBDC), whose features are still ambiguous [8, 26].

**Materials and Methods**

**Specimens**

Between March 1998 and December 2001, we selected our cases by a systematic search through the pathology reports of the Department of Pathology of the University of Palermo.

We identified 48 specimens that were grouped as follows:

A) Inflamed gallbladders and extrahepatic bile ducts: 10 surgical specimens of lithiasic and/or inflamed gallbladders and extrahepatic bile ducts;

B) 15 percutaneous liver biopsy specimens obtained from patients with chronic hepatitis C, with primary biliary cirrhosis or primary sclerosing cholangitis;

C) EBDCs: 13 surgically resected specimens, 10 from gallbladder and 3 from large bile ducts;

D) IBDCs: 10 specimens, 5 obtained by surgical resection and 5 by percutaneous liver biopsy. Two of these cases were associated with sclerosing cholangitis, and one with intrahepatic bile duct stones.

**Immunohistochemistry**

Formalin-fixed, paraffin-embedded tissue sections were stained by Hematoxylin-Eosin and Alcian blue-PAS. Immunohistochemical studies were done using the Avidin-Biotin-Complex (ABC) technique. The primary monoclonal antibodies (mAbs) used were CK7 (clone OV-TL12/30) and CK20 (clone Ks 20.8), both obtained from DAKO (A/S, Glostrup, Denmark).

Sections were cut and then deparaffinized in xylene and rehydrated through alcohols. To improve immunostaining, samples were digested with 0.1% trypsin before incubation with CK7 mAb, and microwaved in 10 mM citrate buffer (pH 6.0) before incubation with CK20 mAb. After incubation with CK7 and CK20 mAbs for 25 minutes at room temperature, sections were incubated with the secondary antibody, which was followed by ABC, as described in the manufacturer’s instructions of Universal LSAB (Dako). Amino-Ethil-Carbazole (AEC) was used as chromogen. The slides were then counterstained with hematoxylin and routinely mounted. As a positive control for CK7, we used intrahepatic bile ducts present in each section; for CK20, immunostaining was carried out on a section of rectal adenocarcinoma. For both mAbs, hepatocytes served as a negative control.

**Quality assessment**

Each section was analyzed by two independent observers. As previously shown by Moll [19], in non-inflamed, non-lithiasic bile system, there was a strong and diffuse immunoreactivity against CK7 mAb, whereas less than 1% of cells were reactive against CK20 mAb (Fig. 1A–B). Therefore, immunostaining for CK7 and CK20 was considered negative when less than 1% of cells were positively stained in the whole section.

**Results**

Results are summarized in Table 1. Group A: Inflamed gallbladders and extrahepatic bile ducts showed focal or diffuse hyperplastic, metaplastic and sometimes dysplastic phenomena. All of them were CK7+/CK20+(Fig. 1C–E).
Cytokeratin 7 and 20 in Bile Tract

A

B

C

D

E

F

G

H
Inflamed intrahepatic bile ducts of liver biopsies were always CK7+/CK20+. In these specimens, metaplastic changes were never expressed.

**Group B:** Inflamed intrahepatic bile ducts of liver biopsies were always CK7+/CK20+. In these specimens, metaplastic changes were never expressed.

**Group C:** Gallbladder carcinomas and EBDCs were mostly CK7+/CK20+. CK20 showed either a focal or a diffuse staining pattern, which was also present in the adjacent dysplastic and/or metaplastic mucosa (Fig. 1F–G). Two cases of this group were CK7+/CK20+. Morphologically, these were mucinous carcinomas with a signet ring cell component. Goblet cell metaplasia was never present in the adjacent mucosa, but there were many areas of diffuse pseudopyloric metaplasia, which is probably due to the use of a different cut-off level for positivity to assess CK20 immunostaining [8].

All intrahepatic bile duct carcinomas were CK7+/CK20+. They never showed metaplastic changes or CK20 expression, neither in neoplastic areas nor in adjacent non-neoplastic bile ducts, except for the case of the patient with intrahepatic bile duct stones, which showed focal positivity for CK20.

Regarding these data, our results are in contrast to those of Rullier [26], who reported that about 47% of peripheral cholangiocarcinomas were positive for CK20, and to the results of Shimonishi [27], who showed scattered positivity for CK20 in moderately and poorly differentiated IBDCs. We found that the large majority of IBDCs did not express CK20, and that the expression pattern of cytokeratins was independent from the differentiation grade. In general, we agree with Rullier, who demonstrated a variability of CK20 positivity according to the different location of tumors in the biliary tract, with an increase in expression ranging from low in IBDCs (called “peripheral carcinomas”) to high in EBDCs (“non peripheral carcinomas”). We found only one case of IBDCs in association with intrahepatic bile duct stones (or hepatolithiasis), which was diffusely positive for CK7 and focally positive for CK20. This cyto-keratin expression pattern was similar to that of EBDCs. As hepatolithiasis is rare in Western countries, we did not find any other case of intrahepatic bile duct stones. Previous studies demonstrated that in livers with hepatolithiasis, intrahepatic bile ducts have metaplastic changes similar to the well-known metaplastic lesions in the gallbladder [14]. These cases sometimes evolve in cholangiocarcinoma [12, 22, 23, 29, 30]. We feel that hepatolithiasis may be the underlying condition related to the appearance of CK20 expression in IBDCs.

Metaplastic phenomena suggest the pluripotentiality of cells during the differentiation process and the liability to determine malignant transformation [13]. In our study, it was evident that CK20 was not only expressed in intestinal metaplastic goblet cells epithelia, but also appeared in hyperplastic or even in morphologically normal epithelia, suggesting that cytokeratin expression may precede morphologic alterations. Thus, CK20 expression in an inflamed bile system could be an “early marker” of metaplasia. About 80% of our EBDCs are...
but as a result of a different multistep pathogenesis. logically different, not because of embryologic reasons, and "non-peripheral" cholangiocarcinomas are immuno- 

fulness. Assessments of larger series of Western and onset of the biliary tumors, and thus have diagnostic use-

sia. We suggest that CK7 and 20 expression patterns can 

normal tissues and related to the appearance of metapla-

sia. CK7 and 20, under specific stimuli, can be different from 

normal and proliferating non neoplastic intrahepatic 

bile ducts. Therefore, under a chronic inflammatory stimulus, a different sequence bypassing the “metaplasia step” could be the starter of most Western peripheral cholangiocarcinomas through the following sequence: ductular proliferation→dysplasia→cancer. Our hypothesis, based on the ability of biliary cells to express both cytokeratins, is supported by experimental observations in a model of bile duct and oval cell proliferation [9] and by molecular studies of rat liver cholangio-
carcinogenesis [24].

In conclusion, our study shows that the expression of CK7 and 20, under specific stimuli, can be different from normal tissues and related to the appearance of metaplasia. We suggest that CK7 and 20 expression patterns can be useful for identifying metaplastic alterations at the onset of the biliary tumors, and thus have diagnostic usefulness. Assessments of larger series of Western and Eastern patients will test the concept that “peripheral” and “non-peripheral” cholangiocarcinomas are immunologically different, not because of embryologic reasons, but as a result of a different multistep pathogenesis.

References


Received: October 30, 2002
Accepted in revised version: February 21, 2003